Lidia I. Malinova

Lidia I. Malinova

Auto-generated profile, based on publicly available information

Lidia I. Malinova

Razumovsky Saratov State Medical University

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
NPN. F. Puchinian
N. F. Puchinian
NFN. V. Furman
N. V. Furman
LML. I. Malinova
L. I. Malinova
PDP. V. Dolotovskaya
P. V. Dolotovskaya
Monitoring of the effectiveness of drug therapy is one of the most debated issues in everyday clinical practice. The emergence of new drugs, methods of analysis, standards, management protocols, and clinical guidelines increases the information load on practitioners and requires a significant investment of time and efforts for self-education. The purpose of the review is to help practitioners in summary form to obtain the necessary information on the issue of control of antiplatelet therapy. The review brings together data from current clinical recommendations on antiplatelet therapy in patients with ischemic heart disease, gives information of existing approaches to control of antiplatelet therapy specified in the guidelines and the consensuses of experts. It presents information on the most common modern methods of monitoring of the antiplatelet therapy effectiveness.

20 August 2013 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
APA. V. Panina
A. V. Panina
NPN. F. Puchinyan
N. F. Puchinyan
YDYa. P. Dovgalevskyi
Ya. P. Dovgalevskyi
NFN. V. Furman
N. V. Furman
PDP. V. Dolotovskaya
P. V. Dolotovskaya
ЯДЯ. П. Довгалевский
Я. П. Довгалевский
Aim. To study the association of plasma D-dimer levels and the risk of thrombotic events in patients hospitalised with acute coronary syndrome (ACS).Material and methods. The study included 70 patients, aged 34-88 years, who were admitted to the Acute Coronary Care Unit with the ACS diagnosis.Results. During the follow-up period, thrombotic events were registered in 12 patients (17%). Three patients with myocardial infarction (MI) suffered recurrent MI. Nine patients were rehospitalised with the unstable angina (UA) diagnosis. All participants were divided into quartiles by the levels of D-dimer (25% percentile 136 ng/ml; median 1250 ng/ml; and 75% percentile 2930 ng/ml). High plasma levels of D-dimer (third quartile) were associated with a 1,5-fold increase in the risk of recurrent thrombotic events among ACS patients.Conclusion. In ACS patients, plasma D-dimer levels could be regarded as one of the additional risk factors of thrombotic events.

1 January 2017 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
LML. I. Malinova
L. I. Malinova
NFN. V. Furman
N. V. Furman
PDP. V. Dolotovskaya
P. V. Dolotovskaya
NPN. F. Puchinian
N. F. Puchinian
IRI. Yu. Radaeva
I. Yu. Radaeva
Цель. Оценить динамику функциональной активности тромбоцитов (ФАТ) на фоне проведения антиагрегантной терапии, включающей как брендированные, так и дженерические препараты, у больных с острым коронарным синдромом с подъемом сегмента ST (ОКСпST) в условиях реальной клинической практики. Материал и методы. Проведено открытое проспективное исследование, включавшее пациентов с ОКСпST, стратифицированных в зависимости от варианта проводимой в стационаре антиагрегантной терапии (сочетание оригинальных и/или дженерических препаратов). В качестве конечной точки использована суррогатная — функциональная активность тромбоцитов (ФАТ), определявшаяся методом импедансной и люминесцентной агрегатометрии в первые и на седьмые сутки с момента манифестации ОКСпST. Результаты. На момент включения в исследование пациенты были сопоставимы по параметрам ФАТ. На фоне двойной антиагрегантной терапии (ДАТ) к седьмым суткам течения ОКСпST достигнуто статистически значимое различие по всем параметрам АДФ-индуцированной агрегации тромбоцитов в зависимости от варианта проводимой антиагрегантной терапии. Выявлены различия динамики параметров АДФ-индуцированной агрегации тромбоцитов в зависимости от варианта ДАТ, включавшей в себя оригинальный препарат или дженерик. Заключение. У больных с ОКСпST степень подавления агрегационной активности тромбоцитов значимо различается в зависимости от варианта проведения антиагрегантной терапии. Использование брендированных и генерических форм одного и того же антиагреганта в одной и той же схеме сопровождается различной степенью и динамикой подавления агрегационной активности тромбоцитов.

10 January 2023 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
LML. I. Malinova
L. I. Malinova
PDP. V. Dolotovskaya
P. V. Dolotovskaya
NFN. V. Furman
N. V. Furman
STS. N. Tolstov
S. N. Tolstov
VKV. A. Klochkov
V. A. Klochkov
TDT. P. Denisova
T. P. Denisova
The objective of the study was to assess the metabolic burden within the concept of vascular ageing in hypertension (HTN) based on the results the able-bodied population study of a large industrial center. Design and methods. A continuous non-randomized cross-sectional study was performed, it included the employees of two medium-sized industrial and commercial enterprises (n = 547). All subjects underwent a formalized medical questionnaire aimed at identifying cardiovascular risk factors, symptoms and signs of cardiovascular pathology, measuring blood pressure (BP), serum levels of total cholesterol, high-density lipoproteins cholesterol, low-density lipoproteins cholesterol, triglycerides, glucose, creatinine and uric acid. Values for 10-year risk of fatal cardiovascular events, total cardiovascular risk, vascular age, and metabolic burden were calculated. Results. In the formed sample, the metabolic burden varied from 0.00 (0.00; 28.57) % in patients with low BP (without antihypertensive medication) to 42,86 (42,86; 57,14) % in patients with the 3rd degree HTN. Positive relationships were found between the magnitude of the metabolic burden, the level of systolic BP (R = 0,432; p < 0,01), diastolic BP (R = 0,360; p < 0,01), 10-year risk of fatal cardiovascular events (R = 0,777; p < 0,01) and total cardiovascular risk (R = 0,781; p < 0,01). Patients with HTN who achieved target BP differed from those with similar BP levels by higher metabolic burden values (p < 0,05). Conclusions. HTN is associated with an increase in metabolic burden, regardless of BP level achieved during treatment. Metabolic burden assessment may be useful in identifying potentially unfavorable HTN phenotypes.

23 November 2016 in Journal of Physics: Conference Series
Verified
Conference Paper
Open access
PDF file
ADA A Dyachenko
A A Dyachenko
LML I Malinova
L I Malinova
VRV P Ryabukho
V P Ryabukho
Red blood cells (RBC) distribution width (RDW) is a promising hematological parameter with broadapplications in clinical practice; in various studies RDWhas been shown to be associated with increased risk of heart failure (HF) in general population. It predicts mortality and other major adverse events in HF patients. In this report new method of RDWmeasurement is presented. It's based on interference color analysis of red blood cells in blood smear and further measurement of its optical thickness. Descriptive statistics of the of the RBC optical thickness distribution in a blood smear were used for RDW estimation in every studied sample. Proposed method is considered to be avoiding type II errors and minimizing the variability of measured RDW.

14 September 2022 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
LML. I. Malinova
L. I. Malinova
STS. N. Tolstov
S. N. Tolstov
TST. S. Silina
T. S. Silina
TDT. P. Denisova
T. P. Denisova
TLT. E. Lipatova
T. E. Lipatova
Objective. To assess the impact of adipose tissue dysfunction for target blood pressure levels achieving in arterial hypertension (AH) and chronic heart failure with preserved left ventricular ejection fraction (HFpEF) in real clinical practice.Materials and methods. We examined 91 elderly patients (> 75 y.o.) with AH and HFpEF during hospital admission. The mass and mass fraction of adipose tissue, serum levels of adipokines (adiponectin, leptin) and proinflammatory cytokines (TNFa and IL6) were assessed. Steady normotension at discharge was used as a marker of the target blood pressure level achievement possibility.Results. By the time of the planned discharge, stable normotension was recorded in 24.2% of patients. In senile patients with failure to achieve normotension, isolated systolic AH was most common - 55.1%. Patients with persistent hypertension at the time of the planned discharge were characterized by a low ability of adipose tissue to secrete adiponectin: 0.05 (0.03; 0.12) vs 0.37 (0.12; 0.5) μg/mL/kg (p = 0.037 ). The minimum values of adiponectin (corrected for adipose tissue mass) were in patients with systolic-diastolic AH (0.04 (0.03; 0.06) μg/ml/kg, Jonkhier-Terpstra test, p = 0.033). A regression model for achieving normotension in senile patients with HFpEF was built with a total percentage of correct classifications of 93.8% before bootstrap and 95.8% after: the maximum values of the Wald statistics were achieved with respect to the predictors "adiponectin", "TNF-a" and "heart rate".Conclusion. The development of adipose tissue dysfunction, accompanied by a decrease in the “rescue hormone” adiponectin synthesis, is associated with the failure to achieve normotension during medication of the inpatient treatment in senile patients with AH and HFpEF.